Alembic Pharmaceuticals Statistics

Total Valuation

Alembic Pharmaceuticals has a market cap or net worth of INR 207.40 billion. The enterprise value is 216.77 billion.

Market Cap	207.40B
Enterprise Value	216.77B

Important Dates

The next estimated earnings date is Tuesday, February 4, 2025.

Earnings Date	Feb 4, 2025
Ex-Dividend Date	Jul 15, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.08%
Shares Change (QoQ)	-0.01%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	58.17M

Valuation Ratios

The trailing PE ratio is 32.07.

PE Ratio	32.07
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	4.24
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 21.61, with an EV/FCF ratio of 267.26.

EV / Earnings	33.52
EV / Sales	3.41
EV / EBITDA	21.61
EV / EBIT	29.91
EV / FCF	267.26

Financial Position

The company has a current ratio of 1.73, with a Debt / Equity ratio of 0.22.

Current Ratio	1.73
Quick Ratio	0.66
Debt / Equity	0.22
Debt / EBITDA	1.06
Debt / FCF	13.15
Interest Coverage	12.46

Financial Efficiency

Return on equity (ROE) is 13.81% and return on invested capital (ROIC) is 8.01%.

Return on Equity (ROE)	13.81%
Return on Assets (ROA)	6.61%
Return on Capital (ROIC)	8.01%
Revenue Per Employee	4.28M
Profits Per Employee	435,308
Employee Count	14,858
Asset Turnover	0.93
Inventory Turnover	0.98

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +35.68% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+35.68%
50-Day Moving Average	1,088.88
200-Day Moving Average	1,048.27
Relative Strength Index (RSI)	44.59
Average Volume (20 Days)	5,084

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Alembic Pharmaceuticals had revenue of INR 63.57 billion and earned 6.47 billion in profits. Earnings per share was 32.89.

Revenue	63.57B
Gross Profit	46.13B
Operating Income	7.24B
Pretax Income	7.05B
Net Income	6.47B
EBITDA	9.83B
EBIT	7.24B
Earnings Per Share (EPS)	32.89

Full Income Statement

Balance Sheet

The company has 1.29 billion in cash and 10.66 billion in debt, giving a net cash position of -9.37 billion.

Cash & Cash Equivalents	1.29B
Total Debt	10.66B
Net Cash	-9.37B
Net Cash Per Share	n/a
Equity (Book Value)	48.88B
Book Value Per Share	248.21
Working Capital	15.91B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.09 billion and capital expenditures -3.28 billion, giving a free cash flow of 811.10 million.

Operating Cash Flow	4.09B
Capital Expenditures	-3.28B
Free Cash Flow	811.10M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 72.56%, with operating and profit margins of 11.39% and 10.17%.

Gross Margin	72.56%
Operating Margin	11.39%
Pretax Margin	11.09%
Profit Margin	10.17%
EBITDA Margin	15.47%
EBIT Margin	11.39%
FCF Margin	1.28%

Dividends & Yields

Alembic Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	37.50%
Years of Dividend Growth	n/a
Payout Ratio	33.43%
Buyback Yield	-0.08%
Shareholder Yield	-0.08%
Earnings Yield	3.12%
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a